OBJECTIVE: To analyze the relationship between microRNA (miR)-21, miR-191 and clinical stage of patients with diffuse large B-cell lymphoma (DLBCL). METHODS: 100 patients with DLBCL treated in Shanxi Fenyang Hospital from January 2019 to January 2021 were selected as the research subjects. All patients was divided into stage I, stage II, stage III and stage IV according to Ann-Arbor (Cotswolds) staging system at admission. The baseline data of patients at different clinical stages were counted and compared in detail. The relationship between the levels of miR-21 and miR-191 and the clinical stage of DLBCL patients was mainly analyzed. RESULTS: Among the 100 patients with DLBCL, there were 15 patients at stage I, 25 patients at stage II, 37 patients at stage III and 23 patients at stage IV. The levels of miR-21 and miR-191 in patients at stage Ⅰ, Ⅱ, Ⅲ and Ⅳ were increased gradually, which showed statistically significant differences (P<0.05). According to Kendall's tau-b correlation analysis, it was found that the levels of miR-21 and miR-191 were positively correlated with the clinical stage of DLBCL patients (r=0.566, 0.636). Multiple logistic regression analysis showed that the overexpression of serum miR-21 and miR-191 was a risk factor for high clinical stage in patients with DLBCL (OR>1, P<0.05). Bivariate Pearson correlation analysis showed that there was a positive correlation between miR-21 and miR-191 levels in patients with DLBCL (r=0.339). CONCLUSION The overexpression of miR-21 and miR-191 in patients with DLBCL is related to high clinical stage.
Humans ; Prognosis ; Lymphoma, Large B-Cell, Diffuse/genetics* ; MicroRNAs/genetics*

Lymphomas are the most common ones of hematologic tumors. In China, Hodgkin's lymphoma accounts for 9% - 10% of lymphomas, which has a good response to chemotherapy, while non-Hodgkin's lymphoma accounts for nearly 90% of lymphomas, and the incidence of which tends to rise in recent years. At present, it was realized that miRNA and lymphomas are closely related to each other. More attention has been paid to the effects of miRNA on the pathophysiological process of lymphoma. This review is focused on miRNA-155, one of the miRNA family members, and its action mechanism in diffuse large B-cell lymphoma, Burkitt lymphoma and Hodgkin's lymphoma, expecting to shed light on the future therapy.
Animals ; Burkitt Lymphoma ; Hodgkin Disease ; Humans ; Lymphoma ; genetics ; Lymphoma, Large B-Cell, Diffuse ; MicroRNAs

Humans ; Lymphoma ; Lymphoma, B-Cell/genetics* ; Lymphoma, Large B-Cell, Diffuse/genetics* ; Mediastinal Neoplasms/genetics* ; Pathology, Molecular

OBJECTIVE: To investigate the expression and significance of LncRNA RP11-513G11.1 in peripheral blood of patients with diffuse large B-cell lymphoma (DLBCL), and to analyze its correlation with clinicopathological features and prognosis of patients. METHODS: The serum samples of 93 patients with DLBCL(DLBCL group) and 62 normal persons (control group) were collected from the Department of Hematology, Southwest Medical University. The expression of RP11-513G11.1 in serum samples was detected by real-time fluorescence quantitative PCR, the relationship between the RP11-513G11.1 expression with clinicopathological characteristics and prognosis was analyzed. RESULTS: Compared with normal control group, the expression of RP11-513G11.1 significantly increased in DLBCL patients (P<0.001). The expression of RP11-513G11.1 not related with the age, sex, course of treatment and germinal center B-cell-like lymphoma(GCB) subtypes of the patients, but it related with the diameter of tumor,Ann Arbor stage,B symptoms,chemosensitivity and the international prognostic index(IPI) (P<0.05). The progression-free survival time and overall survival time of patients, whom with high expression of RP11-513G11.1 were significantly shorter than those of RP11-513G11.1 low expression（P<0.001）. The median progression-free survival time and overall survival time of chemotherapy-sensitive patients were significantly longer than those of chemotherapy-resistant patients (P<0.001). Univariate analysis and multivariate Cox regression analysis showed that Ann Arbor stage, RP11-513G11.1 expression, IPI and chemosensitivity were also the independent factors affecting the prognosis of DLBCL patients（P<0.05）. CONCLUSION RP11-513G11.1 is highly expressed in patients with DLBCL, which is related with the prognosis of DLBCL patients.
B-Lymphocytes ; Germinal Center ; Humans ; Lymphoma, Large B-Cell, Diffuse ; genetics ; Prognosis ; RNA, Long Noncoding ; genetics

<b>OBJECTIVEb>To explore an efficient way to knockout microRNA genes in hemapoietic cell lines with a very low transfection efficiency, so as to facilitate the study of microRNA function in hematopoietic malignancies.

<b>METHODSb>TALE-nucleases was utilized to knockout the microRNA-21 gene in human diffuse large B-cell lymphoma cells (OCI-Ly3). The OCI-Ly3 single cell clones without expression of miR-21 were established through eGFP(+) enrichment, PCR screening, and microRNA quantification. Finally, the miR-21 changes of mutant clones were identified by sequencing.

<b>RESULTSb>Four miR-21-knockouted OCI-Ly3 single-cell-derived clones were established after 2 round transfection and screening. The miR-21 knockout efficiency was around 10/10(6) original cells. Sequencing the mutant clones indicated that miR-21 expression could be drastically reduced by simply altering sequences immediately adjacent to the microRNA duplex.

<b>CONCLUSIONb>This strategy may be applied to knockout any microRNA of interest even in hemapoietic cell lines with very low transfection efficiency.

Myeloid differentiation factor (MyD88) is an important adaptor protein mediating the signal transduction of most Toll-like receptors (TLR), interleukin-1 receptor (IL-1R) and interleukin-18 receptor (IL-18R) that play a key role to mediate innate immune response. Recently, activating of MYD88 L265 mutation has been reported in about of 90% lymphoplasmacytoid lymphoma/Waldenström's Macroglobulinemia, about of 29% activated type diffuse large B-cell lymphoma and other subtypes of B cell tumors demonstrating the MyD88 signaling plays an important role in B cell tumorigenesis, and inhibitors targeting MyD88 might become a new remedy for B cell tumors. In this review, the latest advances in the roles of MyD88 L265P mutation in B cell tumorigenesis were summarized.
Carcinogenesis ; Humans ; Lymphoma, Large B-Cell, Diffuse ; Mutation ; Myeloid Differentiation Factor 88 ; genetics ; Signal Transduction

Gene Expression Profiling ; Genomics ; methods ; Humans ; Lymphoma, Large B-Cell, Diffuse ; classification ; genetics ; pathology ; Prognosis

CD5 Antigens ; Chromosome Aberrations ; Humans ; Lymphoma, Large B-Cell, Diffuse ; complications ; genetics ; Splenic Infarction ; complications

Diffuse large B cell lymphoma (DLBCL) is the most common subtype of invasive non-Hodgkin's lymphoma (NHL), account for 30%-40% of NHL in adults, the 5-year survival rate is approximately 25%. Although there was a standard treatment to DLBCL today, approximately 50% of patients can not be cured. As a result, it is still a diligent direction of the researchers to understand the pathogenesis of DLBCL and to explore new effective treatment. Recently, the study of microRNA is a hot topic in biology, microRNAs are a class of small non-coding RNA that have emerged to regulate various of biological processes. MiR-155 is one of the most well-known oncogenic micro-RNA, miR-155 overexpression has been documented in a number of lymphoid neoplasms, extraordinarily in DLBCL. MiR-155 can promote the occurrence of lymphoma through various signaling pathways, such as the BMP/TGF-β and RhoA pathway, it is expected to become a new target for treatment of DLBCL. This article reviews the role and possible mechanisms of miR-155 in the pathogenesis of DLBCL.
Humans ; Lymphoma, Large B-Cell, Diffuse ; genetics ; metabolism ; MicroRNAs ; metabolism ; Signal Transduction

Diffuse large B-cell lymphoma (DLBCL) as an aggressive lymphoma, there has not a good molecular marker to assess the therapeutic efficacy and prognosis of the disease. As compared with the traditional deteation method, it was found that the circulating tumor DNA (ctDNA) can be used as a non-invasive specific biomarker which can dynamically provide the information about the lymphoma. ctDNA in DLBCL can be obtained by dideoxy chain termination method combined with PCR, so as to detect genetic markers, targeted sequences of gene which is related to lymphoma; the digital PCR (dPCR) for lymphoma somatic mutations and the detection of abnormal methylation; ctDNA is closely related to the diagncsis, therapeutic efficiency and prognosis of DLBCL, thus ctDNA can be used for the early detection, mid-term and prognostic monitoring in DLBCL, which makes ctDNA have a broad clinical applied prospect.
Biomarkers, Tumor ; Circulating Tumor DNA ; Humans ; Lymphoma, Large B-Cell, Diffuse/genetics* ; Polymerase Chain Reaction ; Prognosis